【摘要】 目的 研究康柏西普联合羟苯磺酸钙治疗糖尿病性黄斑水肿(DME)的临床价值。方法 选择50例(50眼)DME患者为研究对象,根据入院顺序将患者分为观察组与对照组,每组25例(25眼)。两组均接受玻璃体腔注射康柏西普治疗,观察组在此基础上联合羟苯磺酸钙胶囊治疗。比较两组治疗前后最佳矫正视力(BCVA)、黄斑中心凹视网膜厚度(CMT)、玻璃体腔内注射药物次数和并发症发生情况。结果 治疗前后两组BCVA比较差异无统计学意义(P>0.05)；治疗后1、2、3个月,两组BCVA均高于本组治疗前,差异有统计学意义(P<0.05)。治疗后1、2、3个月,两组CMT均小于本组治疗前,且观察组CMT分别为(509.60±65.12)、(424.13±53.90)、(316.01±22.24)μm,小于对照组的(549.23±60.18)、(498.12±56.12)、(364.48±55.45)μm,差异有统计学意义(P<0.05)。观察组治疗后1年内平均注射次数(3.3±0.5)次显著少于对照组的(4.2±0.7)次,差异有统计学意义(P<0.05)。观察组并发症发生率为4.0%,与对照组的12.0%比较差异无统计学意义(P>0.05)。所有并发症均为轻度,休息后均获得自行缓解。结论 对DME患者联合康柏西普与羟苯磺酸钙共同治疗可显著改善患者视力并降低CMT水平,较康柏西普单独治疗具有更高的安全性,并可更好地发挥药物协同作用,对改善黄斑水肿,促进疾病的康复具有积极意义。更多还原

【Abstract】 Objective To study the clinical value of Conbercept in combination with calcium dobesilate in the treatment of diabetic macular edema(DME). Methods A total of 50 patients(50 eyes) with DME were selected for the study, and the patients were divided into observation group and control group according to the order of admission, with 25 cases(25 eyes) in each group. Both groups were treated with vitreous cavity injection of Conbercept, and the observation group was treated with calcium dobesilate capsule on this basis. The best corrected visual acuity(BCVA), central macular thickness(CMT) before and after treatment, number of intravitreal injections, and occurrence of complications were compared between the two groups. Results There was no statistically significant difference in BCVA between the two groups before and after treatment(P>0.05). At 1,2 and 3 months after treatment, the BCVA in both groups was higher than that before treatment in this group,and the difference was statistically significant(P<0.05). At 1, 2 and 3 months after treatment, the CMT in both groups was less than that before treatment in this group; the CMT in the observation group were(509.60±65.12),(424.13±53.90) and(316.01±22.24) μm, which were less than(549.23±60.18),(498.12±56.12) and(364.48±55.45) μm in the control group; the differences were statistically significant(P<0.05). The mean number of injections in the observation group was(3.3±0.5) injections within 1 year after treatment, which was significantly less than(4.2±0.7) injections in the control group, and the difference was statistically significant(P<0.05). The incidence of complications in the observation group was 4.0%, and the difference was not statistically significant compared with 12.0% in the control group(P>0.05). All the complications were mild and self relieved after rest. Conclusion Combined treatment of DME patients with Conbercept and calcium dobesilate can significantly improve the patient’s visual acuity and reduce the level of CMT, which is safer than the treatment of Conbercept alone, and can better play the role of drug synergy, which is of positive significance for improving macular edema and promoting the recovery of the disease.更多还原